TABLE 4.

RISK OF FIVE-YEAR NON-RELAPSE MORTALITY AS A FUNCTION OF PULMONARY FUNCTION PARAMETERS

PFT parameter	N	Unadjusted HR (95% CI)	P-value	Adjusted HR‡ (95% CI)	P-value
LFS category	1855
0	816	Referent		Referent
1	839	1.47 (1.17 – 1.85)	0.001	1.37 (1.08 – 1.75)	0.011
2	182	3.38 (2.53 – 4.53)	< 0.0005	3.02 (2.11 – 4.33)	< 0.0005
3	18	7.80 (4.15 – 14.68)	< 0.0005	8.56 (4.54 – 16.14)	< 0.0005
			Trend <0.0005		Trend <0.0005
FEV1	1999
≥ 80%	1451	Referent		Referent
70–79%	327	1.76 (1.38 – 2.24)	< 0.0005	1.56 (1.19 – 2.06)	0.002
60–69%	139	2.33 (1.68 – 3.25)	< 0.0005	2.57 (1.75 – 3.76)	< 0.0005
< 60%	82	5.79 (4.28 – 7.85)	< 0.0005	4.88 (3.19 – 7.47)	< 0.0005
			Trend <0.0005		Trend <0.0005
FVC	1999
≥ 80%	1612	Referent		Referent
70–79%	339	2.37 (1.84 – 3.04)	< 0.0005	2.26 (1.72 – 2.97)	< 0.0005
60–69%	100	2.74 (1.96 – 3.85)	< 0.0005	2.76 (1.84 – 4.15)	< 0.0005
< 60%	48	6.65 (4.54 – 9.76)	< 0.0005	7.79 (5.00 – 12.14)	< 0.0005
			Trend <0.0005		Trend <0.0005
TLC	1870
≥ 80%	1650	Referent		Referent
70–79%	159	2.42 (1.80 – 3.24)	< 0.0005	2.18 (1.56 – 3.04)	< 0.0005
60–69%	46	4.28 (2.79 – 6.56)	< 0.0005	4.03 (2.65 – 6.12)	< 0.0005
< 60%	15	2.47 (1.02 – 6.02)	0.046	3.42 (1.42 – 8.23)	0.006
			Trend <0.0005		Trend <0.0005
DLCO	1856
≥ 80%	945	Referent		Referent
70–79%	397	0.99 (0.74 – 1.33)	0.966	1.05 (0.78 – 1.42)	0.745
60–69%	305	2.04 (1.57 – 2.66)	< 0.0005	1.88 (1.38 – 2.57)	< 0.0005
< 60%	209	2.59 (1.96 – 3.43)	< 0.0005	2.58 (1.86 – 3.57)	< 0.0005
			Trend <0.0005		Trend <0.0005

^‡Adjusted for age, sex, disease risk, conditioning regimen, HLA status, acute GVHD grade, CMV status of donor and patient and pre-HCT lung function. Results do not include patients who had recurrent malignancy before pulmonary function was evaluated.